Neither Ambroxol nor Erdosteine (Vestein) Should Be Used for Mucopurulent Sinusitis
The most recent and authoritative guidelines explicitly do not recommend mucolytic agents for the treatment of acute or chronic sinusitis. The 2025 American Academy of Otolaryngology-Head and Neck Surgery clinical practice guideline on adult sinusitis makes no mention of mucolytics as a recommended therapy for either acute bacterial rhinosinusitis (ABRS) or chronic rhinosinusitis (CRS) 1, 2.
What the Guidelines Actually Recommend
For symptomatic relief of ABRS, the 2025 guideline recommends only 1:
- Analgesics for facial pain relief
- Topical intranasal corticosteroids (number needed to treat = 11 for modest symptom improvement)
- Nasal saline irrigation for possible symptom relief
The guideline explicitly states that interventions with "questionable, unknown or unproven efficacy" should be discouraged, specifically listing guaifenesin (an expectorant) in this category 1. Mucolytics fall into this same evidence-poor category.
Why Mucolytics Are Not Recommended
The evidence quality for mucolytics in sinusitis is Grade D at best - meaning it relies on "first principles" rather than solid clinical trial data 1. The guideline development process reviewed 14 guidelines, 194 systematic reviews, and 133 RCTs, yet mucolytics did not make the cut for recommended therapies 2.
Addressing the Specific Agents You Asked About
Erdosteine (Vestein)
- One small pilot study (n=not specified) showed some benefit in chronic rhinosinusitis with nasal polyps 3
- A pediatric study in acute rhinosinusitis showed no significant difference between erdosteine and placebo (78% vs 74.4% improvement) 4
- The FDA drug label you provided 5 is actually for tacrolimus ointment for atopic dermatitis, not erdosteine - this appears to be a database error
Ambroxol
- No high-quality evidence exists for its use specifically in sinusitis
- One comparative study looked at N-acetylcysteine vs ambroxol in recurrent acute rhinosinusitis but provided no clear superiority data 6
- Evidence exists for inhaled ambroxol in mucopurulent sputum from lower respiratory tract conditions 7, but this does not translate to sinusitis
The Clinical Reality
While a general review suggests mucolytics may have a role in "upper respiratory airways infections, including bronchitis, sinusitis, and rhinosinusitis" 8, this represents older, lower-quality evidence that has been superseded by the rigorous 2025 guideline process.
The quality improvement opportunity explicitly stated in the guideline is to "discourage interventions with questionable, unknown or unproven efficacy" 1. Mucolytics fall squarely into this category for sinusitis.
What You Should Do Instead
For acute bacterial rhinosinusitis:
- Consider watchful waiting (now extended to all patients with uncomplicated ABRS, not just mild cases) 2
- If antibiotics are needed: amoxicillin with or without clavulanate as first-line 2
- For symptom relief: topical intranasal corticosteroids and nasal saline irrigation 1
- Analgesics for pain 1
For chronic rhinosinusitis:
- Topical intranasal corticosteroids remain the mainstay
- Biologics may be considered in patients with polyps 2
- Avoid empiric antibiotics solely as third-party requirements 2
Common Pitfall to Avoid
Do not prescribe mucolytics simply because they are commonly used in clinical practice or because patients expect them. The 2025 guideline represents the most comprehensive, evidence-based approach to sinusitis management and explicitly excludes these agents from recommended therapy.